Tags

Type your tag names separated by a space and hit enter

COVID-19 Vaccine: A comprehensive status report.
Virus Res. 2020 10 15; 288:198114.VR

Abstract

The current COVID-19 pandemic has urged the scientific community internationally to find answers in terms of therapeutics and vaccines to control SARS-CoV-2. Published investigations mostly on SARS-CoV and to some extent on MERS has taught lessons on vaccination strategies to this novel coronavirus. This is attributed to the fact that SARS-CoV-2 uses the same receptor as SARS-CoV on the host cell i.e. human Angiotensin Converting Enzyme 2 (hACE2) and is approximately 79% similar genetically to SARS-CoV. Though the efforts on COVID-19 vaccines started very early, initially in China, as soon as the outbreak of novel coronavirus erupted and then world-over as the disease was declared a pandemic by WHO. But we will not be having an effective COVID-19 vaccine before September, 2020 as per very optimistic estimates. This is because a successful COVID-19 vaccine will require a cautious validation of efficacy and adverse reactivity as the target vaccinee population include high-risk individuals over the age of 60, particularly those with chronic co-morbid conditions, frontline healthcare workers and those involved in essentials industries. Various platforms for vaccine development are available namely: virus vectored vaccines, protein subunit vaccines, genetic vaccines, and monoclonal antibodies for passive immunization which are under evaluations for SARS-CoV-2, with each having discrete benefits and hindrances. The COVID-19 pandemic which probably is the most devastating one in the last 100 years after Spanish flu mandates the speedy evaluation of the multiple approaches for competence to elicit protective immunity and safety to curtail unwanted immune-potentiation which plays an important role in the pathogenesis of this virus. This review is aimed at providing an overview of the efforts dedicated to an effective vaccine for this novel coronavirus which has crippled the world in terms of economy, human health and life.

Links

PMC Free PDF

Authors+Show Affiliations

Kaur SP
Department of Microbiology, Ram Lal Anand College, University of Delhi, Benito Juarez Road, New Delhi 110021, India.
Gupta V
Department of Microbiology, Ram Lal Anand College, University of Delhi, Benito Juarez Road, New Delhi 110021, India. Electronic address: vandanagupta72@rediffmail.com.

MeSH

Angiotensin-Converting Enzyme 2Antibodies, ViralBetacoronavirusCOVID-19COVID-19 VaccinesClinical Trials as TopicCoronavirus InfectionsGenetic VectorsHumansImmunity, InnateImmunization, PassiveImmunogenicity, VaccinePandemicsPatient SafetyPeptidyl-Dipeptidase APneumonia, ViralReceptors, VirusSARS-CoV-2Vaccines, AttenuatedVaccines, DNAVaccines, SubunitVaccines, Virus-Like ParticleViral VaccinesCOVID-19 Serotherapy

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32800805

Citation

Kaur, Simran Preet, and Vandana Gupta. "COVID-19 Vaccine: a Comprehensive Status Report." Virus Research, vol. 288, 2020, p. 198114.
Kaur SP, Gupta V. COVID-19 Vaccine: A comprehensive status report. Virus Res. 2020;288:198114.
Kaur, S. P., & Gupta, V. (2020). COVID-19 Vaccine: A comprehensive status report. Virus Research, 288, 198114. https://doi.org/10.1016/j.virusres.2020.198114
Kaur SP, Gupta V. COVID-19 Vaccine: a Comprehensive Status Report. Virus Res. 2020 10 15;288:198114. PubMed PMID: 32800805.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - COVID-19 Vaccine: A comprehensive status report. AU - Kaur,Simran Preet, AU - Gupta,Vandana, Y1 - 2020/08/13/ PY - 2020/07/03/received PY - 2020/08/06/revised PY - 2020/08/07/accepted PY - 2020/8/18/pubmed PY - 2020/10/8/medline PY - 2020/8/18/entrez KW - COVID-19 KW - Clinical Trials KW - Convalescent Plasma Therapy KW - Monoclonal Antibodies KW - SARS-CoV-2 KW - Vaccine SP - 198114 EP - 198114 JF - Virus research JO - Virus Res VL - 288 N2 - The current COVID-19 pandemic has urged the scientific community internationally to find answers in terms of therapeutics and vaccines to control SARS-CoV-2. Published investigations mostly on SARS-CoV and to some extent on MERS has taught lessons on vaccination strategies to this novel coronavirus. This is attributed to the fact that SARS-CoV-2 uses the same receptor as SARS-CoV on the host cell i.e. human Angiotensin Converting Enzyme 2 (hACE2) and is approximately 79% similar genetically to SARS-CoV. Though the efforts on COVID-19 vaccines started very early, initially in China, as soon as the outbreak of novel coronavirus erupted and then world-over as the disease was declared a pandemic by WHO. But we will not be having an effective COVID-19 vaccine before September, 2020 as per very optimistic estimates. This is because a successful COVID-19 vaccine will require a cautious validation of efficacy and adverse reactivity as the target vaccinee population include high-risk individuals over the age of 60, particularly those with chronic co-morbid conditions, frontline healthcare workers and those involved in essentials industries. Various platforms for vaccine development are available namely: virus vectored vaccines, protein subunit vaccines, genetic vaccines, and monoclonal antibodies for passive immunization which are under evaluations for SARS-CoV-2, with each having discrete benefits and hindrances. The COVID-19 pandemic which probably is the most devastating one in the last 100 years after Spanish flu mandates the speedy evaluation of the multiple approaches for competence to elicit protective immunity and safety to curtail unwanted immune-potentiation which plays an important role in the pathogenesis of this virus. This review is aimed at providing an overview of the efforts dedicated to an effective vaccine for this novel coronavirus which has crippled the world in terms of economy, human health and life. SN - 1872-7492 UR - https://www.unboundmedicine.com/medline/citation/32800805/COVID_19_Vaccine:_A_comprehensive_status_report_ DB - PRIME DP - Unbound Medicine ER -